🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Better Options for Lymphatic Filariasis Treatment

RecruitingPhase 3Ages any - anyAllMedicines Development for Global Health
NCT07159373 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are: 1. Does MoxDA clear infection in people with lymphatic filariasis ? 2. Does MoxDA cause any medical problems in infected and uninfected people? Researchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems. Participants will: 1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis 2. Take 3 single doses of MoxDA or IDA, 12 months apart 3. Visit their village

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Provision of signed and dated informed consent. 2. Resident in one of the study locations. Exclusion Criteria: There are no exclusion criteria to participation in the study. Treatment Exclusion Criteria: Participants are ineligible to receive the treatment regimen allocated to their village if they meet any of the following criteria: 1. Severe illness (any illness that is severe enough to interfere with activities of daily living); 2. Known or suspected allergy to ivermectin, moxidectin, diethylcarbamazine or albendazole; 3. Pregnant; 4. Breastfeeding a baby within 7 days of birth; 5. Age \< 4 years for villages randomised to moxidectin, diethylcarbamazine, and albendazole (MoxDA); or 6. Age \< 2 years or weight \< 15 kg for villages randomized to ivermectin, diethylcarbamazine and albendazole (IDA).
💊

What it tests

  • MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole
  • IDA - Ivermectin + DEC + albendazole
📍

Where

1 site
Ministry of Health and Medical Services Fiji
Suva, Fiji
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy